Yin G - Search Results

1

Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathway.

Meng D, Yin G, Chen S, Zhang X, Yu W, Wang L, Liu H, Jiang W, Sun Y, Zhang F. Meng D, et al. Among authors: yin g. Eur J Pharmacol. 2024 Aug 15;977:176737. doi: 10.1016/j.ejphar.2024.176737. Epub 2024 Jun 10. Eur J Pharmacol. 2024. PMID: 38866362

2

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review.

Sun F, Yang X, Ma C, Zhang S, Yu L, Lu H, Yin G, Liang P, Feng Y, Zhang F. Sun F, et al. Among authors: yin g. Diabetes Metab Syndr Obes. 2021 Sep 15;14:4015-4030. doi: 10.2147/DMSO.S326054. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 34552341 Free PMC article. Review.

3

Therapeutic potential and research progress of diosgenin for lipid metabolism diseases.

Zhang SZ, Liang PP, Feng YN, Yin GL, Sun FC, Ma CQ, Zhang FX. Zhang SZ, et al. Drug Dev Res. 2022 Dec;83(8):1725-1738. doi: 10.1002/ddr.21991. Epub 2022 Sep 20. Drug Dev Res. 2022. PMID: 36126194 Review.

4

Effects of Acupuncture-Related Therapies in the Rehabilitation of Patients with Post-Stroke Aphasia-A Network Meta-Analysis of Randomized Controlled Trials.

Liang P, Li Y, Feng Y, Yin G, Chen S, Liu X, Zhang F. Liang P, et al. Among authors: yin g. Brain Sci. 2022 Sep 23;12(10):1282. doi: 10.3390/brainsci12101282. Brain Sci. 2022. PMID: 36291216 Free PMC article. Review.

5

Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.

Feng Y, Sun W, Sun F, Yin G, Liang P, Chen S, Liu X, Jiang T, Zhang F. Feng Y, et al. Among authors: yin g. Drug Des Devel Ther. 2022 Nov 4;16:3829-3845. doi: 10.2147/DDDT.S386982. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36388082 Free PMC article. Review.

6

Shuangyu Tiaozhi decoction alleviates non-alcoholic fatty liver disease by improving lipid deposition, insulin resistance, and inflammation in vitro and in vivo.

Yin G, Liang H, Sun W, Zhang S, Feng Y, Liang P, Chen S, Liu X, Pan W, Zhang F. Yin G, et al. Front Pharmacol. 2022 Nov 23;13:1016745. doi: 10.3389/fphar.2022.1016745. eCollection 2022. Front Pharmacol. 2022. PMID: 36506575 Free PMC article.

7

Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.

Chen S, Sun S, Feng Y, Li X, Yin G, Liang P, Yu W, Meng D, Zhang X, Liu H, Zhang F. Chen S, et al. Among authors: yin g. Eur J Pharmacol. 2023 Aug 5;952:175808. doi: 10.1016/j.ejphar.2023.175808. Epub 2023 May 30. Eur J Pharmacol. 2023. PMID: 37263401

8

[Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].

Yin GL, Liang HY, Liang PP, Feng YN, Chen SW, Liu XY, Pan WC, Zhang FX. Yin GL, et al. Zhongguo Zhong Yao Za Zhi. 2023 Apr;48(7):1760-1769. doi: 10.19540/j.cnki.cjcmm.20221123.401. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 37282950 Chinese.

9

Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver.

Meng D, Zhang F, Yu W, Zhang X, Yin G, Liang P, Feng Y, Chen S, Liu H. Meng D, et al. Among authors: yin g. Diabetes Metab Syndr Obes. 2023 Dec 8;16:4043-4064. doi: 10.2147/DMSO.S437865. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 38089432 Free PMC article. Review.

10

[Diosgenin alleviates NAFLD induced by a high-fat diet in rats via mTOR/SREBP-1c/HSP60/MCAD/SCAD signaling pathway].

Chen SW, Yin GL, Song CY, Meng DC, Yu WF, Zhang X, Feng YN, Liang PP, Zhang FX. Chen SW, et al. Zhongguo Zhong Yao Za Zhi. 2023 Oct;48(19):5304-5314. doi: 10.19540/j.cnki.cjcmm.20230601.705. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114120 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,556 results

Search Page

Filters